Antifungals in Clinical Use and the Pipeline.

Journal Article (Journal Article;Review)

Over the past 15 years, there has been an increase in the development and utilization of newer antifungal agents. The ideal antifungal, however, in regard to spectrum of activity, pharmacokinetic/pharmacodynamic properties, development of resistance, safety, and drug interaction profile remains elusive. This article reviews pharmacologic aspects of Food and Drug Administration-approved polyenes, flucytosine, azoles, and echinocandins as well as promising pipeline antifungal agents. Unique properties of these newer agents are highlighted. The clinical role of established and investigational antifungal agents as treatment and/or prevention of invasive fungal infections is discussed.

Full Text

Duke Authors

Cited Authors

  • Johnson, MD

Published Date

  • June 2021

Published In

Volume / Issue

  • 35 / 2

Start / End Page

  • 341 - 371

PubMed ID

  • 34016281

Electronic International Standard Serial Number (EISSN)

  • 1557-9824

Digital Object Identifier (DOI)

  • 10.1016/j.idc.2021.03.005


  • eng

Conference Location

  • United States